Compass Therapeutics Appoints New CMO, Elects Director
Ticker: CMPX · Form: 8-K · Filed: May 28, 2024 · CIK: 1738021
| Field | Detail |
|---|---|
| Company | Compass Therapeutics, Inc. (CMPX) |
| Form Type | 8-K |
| Filed Date | May 28, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $45,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-appointment, executive-compensation
TL;DR
Compass Therapeutics brings in a new CMO and adds a director to the board.
AI Summary
Compass Therapeutics, Inc. announced on May 28, 2024, the appointment of Dr. Michael J. Ybarra as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member can signal strategic shifts in the company's R&D focus and governance, potentially impacting future drug development and business strategy.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategic direction and operational execution.
Key Players & Entities
- Compass Therapeutics, Inc. (company) — Registrant
- Dr. Michael J. Ybarra (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Kelly (person) — Elected to Board of Directors
- May 28, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer of Compass Therapeutics?
Dr. Michael J. Ybarra has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors of Compass Therapeutics?
Ms. Sarah E. Kelly has been elected to the Board of Directors.
What is the exact date of this Form 8-K filing?
The exact date of this Form 8-K filing is May 28, 2024.
What other information is disclosed regarding executive officers?
The filing also discloses compensatory arrangements for certain officers.
What is the principal executive office address of Compass Therapeutics?
The principal executive office address is 80 Guest Street, Suite 601, Boston, Massachusetts 02135.
Filing Stats: 1,069 words · 4 min read · ~4 pages · Grade level 11.3 · Accepted 2024-05-28 16:09:10
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CMPX NASDAQ Capital
- $45,000 — Company will compensate Dr. Bisker-Leib $45,000 annually, to be paid in quarterly insta
Filing Documents
- f8k_052824.htm (8-K) — 19KB
- exh_101.htm (EX-10.1) — 48KB
- exh_102.htm (EX-10.2) — 19KB
- exh_991.htm (EX-99.1) — 3KB
- 0001171843-24-003129.txt ( ) — 307KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_052824_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On May 28, 2024, the Company issued a press release announcing the resignation of Dr. Bisker-Leib, from her position as Chief Executive Officer, and the appointment of Dr. Schuetz as Chief Executive Officer. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit 10.1 Separation Agreement, dated May 28, 2024, by and between Compass Therapeutics, Inc. and Vered Bisker-Leib, PhD 10.2 Consulting Agreement, dated May 28, 2024, by and between Compass Therapeutics, Inc. and Vered Bisker-Leib, PhD 99.1 Press Release, dated May 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: May 28, 2024 By: /s/ Neil Lerner Neil Lerner VP Finance